# US 11,077,157 B2 · Medicinal composition for treating fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,157 B2
- Document ID: US11077157B2
- Status: Granted
- Kind: B2
- Application number: 16/077,840
- Filed: 2017-02-15
- Published: 2019-05-23
- Granted: 2021-08-03
- Earliest claimed: 2016-02-16
- Assignees: Osaka University
- Applicants: Osaka University
- Inventors: Fuminori Sakurai; Hiroyuki Mizuguchi
- Web page: https://patentgrep.com/patent/US11077157B2

## CPC

- A61K 35/765: Reovirus; Rotavirus
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides a pharmaceutical composition for use in treating fibrosis comprising a reovirus as an active ingredient.

## Claims

### Claim 1

A method for treating fibrosis in a human subject in need thereof, comprising administering a reovirus to the human subject, wherein the fibrosis is in an organ selected from liver, lung, heart and kidney, or the fibrosis is skin fibrosis, and the reovirus is strain Dearing of mammalian orthoreovirus type 3.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the reovirus is a live virus.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the reovirus is an inactivated virus.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the fibrosis is in an organ selected from liver, lung, heart, and kidney.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the fibrosis is in the liver, lung, or heart.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the fibrosis is in the liver or lung.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the human subject is suffering from a disease or a condition selected from liver fibrosis, liver cirrhosis, hepatitis B, hepatitis c, alcoholic hepatitis, non-alcoholic steatohepatitis, pulmonary fibrosis, cardiac fibrosis associated with myocardial infarction, and renal fibrosis associated with chronic renal disease.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the human subject is suffering from liver fibrosis, liver cirrhosis, hepatitis B, hepatitis c, alcoholic hepatitis, non-alcoholic steatohepatitis, or pulmonary fibrosis.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the human subject is suffering from cardiac fibrosis associated with myocardial infarction.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the fibrosis is skin fibrosis.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the human subject is suffering from scleroderma.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the reovirus is administered intravenously.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the fibrosis is in the liver.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the fibrosis is in the lung.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the fibrosis is in the heart.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the fibrosis is in the kidney.

### Claim 17

A method for treating skin fibrosis in a human subject in need thereof, comprising administering a Dearing strain of mammalian orthoreovirus type 3 to the human subject.